Biochemistry and Structural Biology  Back to Main

Faculty Detail    
Campus Address WTI 420 Zip 6810
Phone  (205) 934-2898
Other websites

Undergraduate  Duke University    1995  AB Chemistry 
Medical School  Duke University School of Meidcine    1999  MD 
Residency  Medical University of South Carolina    2005  Urology 
Fellowship  National Cancer Institiute    2007  Urologic Oncology 

Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Urology   Urology Chair Office Professor
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Professor
Center  General Clinical Research Center  Nephrology Research & Training Center Professor

Graduate Biomedical Sciences Affiliations
Biochemistry and Structural Biology 
Genetics, Genomics and Bioinformatics 

Society Memberships
Organization Name Position Held Org Link
American Association of Cancer Research     
American Urological Association     

Research/Clinical Interest
The Metabolic Basic of Kidney Cancer
Our laboratory’s principal focus has been to study the metabolic alterations of kidney cancer, also referred to as renal cell carcinoma (RCC). We study both rare hereditary forms of RCC as well as in sporadic kidney cancer. We are interested in hereditary forms of renal cancer as we believe the study of these disease variants can provide insight into more common, sporadic forms of this disease. We are interested in how metabolic remodeling contributes to tumor formation, progression, as well as response to therapy. In particular, our laboratory is interested in the connection between tumor metabolism and epigenetics. The overarching goal is to perform mechanistic studies that will advance our current knowledge base of kidney cancer in order to develop better methods to treat patients with advanced disease.

Selected Publications 
Publication PUBMEDID
L-2-Hydroxyglutarate: An Epigenetic Modifier and Putative Oncometabolite in Renal Cancer.
Shim EH, Livi CB, Rakheja D, Tan J, Benson D, Parekh V, Kho EY, Ghosh AP, Kirkman R, Velu S, Dutta S, Chenna B, Rea SL, Mishur RJ, Li Q, Johnson-Pais TL, Guo L, Bae S, Wei S, Block K, Sudarshan S.
Cancer Discov. 2014 Nov;4(11):1290-8. doi: 10.1158/2159-8290.CD-13-0696. Epub 2014 Sep 2. 
The oncometabolite fumarate promotes pseudohypoxia through noncanonical activation of NF-κB signaling.
Shanmugasundaram K, Nayak B, Shim EH, Livi CB, Block K, Sudarshan S.
J Biol Chem. 2014 Aug 29;289(35):24691-9. doi: 10.1074/jbc.M114.568162. Epub 2014 Jul 15. 
The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling.
Sullivan LB, Martinez-Garcia E, Nguyen H, Mullen AR, Dufour E, Sudarshan S, Licht JD, Deberardinis RJ, Chandel NS.
Mol Cell. 2013 Jul 25;51(2):236-48. doi: 10.1016/j.molcel.2013.05.003. Epub 2013 Jun 6. Erratum in: Mol Cell. 2013 Jul 25;51(2):273. 
Metabolism of kidney cancer: from the lab to clinical practice.
Sudarshan S, Karam JA, Brugarolas J, Thompson RH, Uzzo R, Rini B, Margulis V, Patard JJ, Escudier B, Linehan WM.
Eur Urol. 2013 Feb;63(2):244-51. doi: 10.1016/j.eururo.2012.09.054. Epub 2012 Sep 28. Review. 
Stabilization of HIF-2α through redox regulation of mTORC2 activation and initiation of mRNA translation.
Nayak BK, Feliers D, Sudarshan S, Friedrichs WE, Day RT, New DD, Fitzgerald JP, Eid A, Denapoli T, Parekh DJ, Gorin Y, Block K.
Oncogene. 2013 Jun 27;32(26):3147-55. doi: 10.1038/onc.2012.333. Epub 2012 Aug 6. 
PI3K regulation of the SKP-2/p27 axis through mTORC2.
Shanmugasundaram K, Block K, Nayak BK, Livi CB, Venkatachalam MA, Sudarshan S.
Oncogene. 2013 Apr 18;32(16):2027-36. doi: 10.1038/onc.2012.226. Epub 2012 Jun 25. 
Nox4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6- and 8- production.
Fitzgerald JP, Nayak B, Shanmugasundaram K, Friedrichs W, Sudarshan S, Eid AA, DeNapoli T, Parekh DJ, Gorin Y, Block K.
PLoS One. 2012;7(1):e30712. doi: 10.1371/journal.pone.0030712. Epub 2012 Jan 27. 
Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasion.
Sudarshan S, Shanmugasundaram K, Naylor SL, Lin S, Livi CB, O'Neill CF, Parekh DJ, Yeh IT, Sun LZ, Block K.
PLoS One. 2011;6(6):e21037. doi: 10.1371/journal.pone.0021037. Epub 2011 Jun 14. 
Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species.
Sudarshan S, Sourbier C, Kong HS, Block K, Valera Romero VA, Yang Y, Galindo C, Mollapour M, Scroggins B, Goode N, Lee MJ, Gourlay CW, Trepel J, Linehan WM, Neckers L.
Mol Cell Biol. 2009 Aug;29(15):4080-90. doi: 10.1128/MCB.00483-09. Epub 2009 May 26. 

tumor metabolism, epigenetics, renal cancer